83
Participants
Start Date
March 31, 2014
Primary Completion Date
March 31, 2019
Study Completion Date
August 31, 2019
Eltrombopag
This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
Placebo
This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
Department of Obstetrics & Gynecology and Department of Oncology Chang Gung Memorial Hospital, Chiayi City
Department of Obstetrics & Gynecology Chang Gung Memorial Hospital, Kaohsiung City
Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Division of Oncology Chang Gung Memorial Hospital, Linkou District
Collaborators (1)
Novartis
INDUSTRY
Chang Gung Memorial Hospital
OTHER